Sanofi, eyeing impurity concerns, pulls hypertension meds in Korea and the UK. Could the next big 'sartan' recall be on the horizon?

Looking to get the jump on impurity concerns first raised in Canada and Europe, Sanofi has rescinded a clutch of blood pressure drugs in Asia and the U.K. It's far from the only company whose meds are under scrutiny, potentially signaling the next widespread recall of a popular hypertension therapy.